Compare RLJ & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | ANNX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 918.2M |
| IPO Year | 2011 | 2020 |
| Metric | RLJ | ANNX |
|---|---|---|
| Price | $8.39 | $5.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $8.75 | ★ $16.50 |
| AVG Volume (30 Days) | 1.6M | ★ 2.3M |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | ★ 7.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $1,351,163,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | $188.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.16 | $1.29 |
| 52 Week High | $9.85 | $7.18 |
| Indicator | RLJ | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 68.99 | 39.79 |
| Support Level | $7.26 | $5.46 |
| Resistance Level | $7.92 | $5.79 |
| Average True Range (ATR) | 0.22 | 0.42 |
| MACD | 0.09 | -0.19 |
| Stochastic Oscillator | 98.70 | 6.46 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.